AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32977180 — intervention group
Group type: COMPARATOR
Intervention: Regional growth technique (control)
Number of subjects: 85
Study 35675601 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive azithromycin initiated after skin incision
Number of subjects: 2013
Study 35675601 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive azithromycin initiated 0-30 minutes before skin incision
Number of subjects: 2013
Study 35675601 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive azithromycin initiated more than 30-60 minutes before skin incision
Number of subjects: 2013
Study 35675601 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive azithromycin initiated more than 60 minutes before skin incision
Number of subjects: 2013
Study 35675601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2013
Study 33231285 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for 35 cycles
Number of subjects: 262
Study 33231285 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (investigator's choice of carboplatin plus paclitaxel or pemetrexed Q3W with optional pemetrexed maintenance)
Number of subjects: 262
Study 33403734 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose remifentanil
Number of subjects: 39
Study 33403734 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose remifentanil
Number of subjects: 39
Study 33403734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 35854270 — intervention group
Group type: EXPERIMENTAL
Intervention: ReCoN intervention (Reducing Coercion in Norway)
Number of subjects: 0
Study 33598874 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI (100/31.25/25 μg, 100/62.5/25 μg, 200/31.25/25 μg, 200/62.5/25 μg)
Number of subjects: 1891
Study 33598874 — intervention group
Group type: COMPARATOR
Intervention: FF/VI (100/25 μg, 200/25 μg)
Number of subjects: 1891
Study 33598874 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI and FF/VI
Number of subjects: 1891
Study 32758049 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT (MB)
Number of subjects: 120
Study 32758049 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT (PA+MB)
Number of subjects: 120
Study 32758049 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT (PA)
Number of subjects: 120
Study 32758049 — intervention group
Group type: EXPERIMENTAL
Intervention: PA
Number of subjects: 120
Study 32758049 — intervention group
Group type: EXPERIMENTAL
Intervention: MB
Number of subjects: 120
Study 32758049 — intervention group
Group type: EXPERIMENTAL
Intervention: PA+MB
Number of subjects: 120
Study 32758049 — intervention group
Group type: EXPERIMENTAL
Intervention: LLL
Number of subjects: 120
Study 32758049 — intervention group
Group type: COMPARATOR
Intervention: S (saline)
Number of subjects: 120
Study 34649396 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Intelligence Counseling Intervention (eight 1-hour weekly sessions)
Number of subjects: 0
Study 34649396 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-list control)
Number of subjects: 0
Study 36130208 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional cash transfer program
Number of subjects: 443
Study 36130208 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled direct effect (CDE) of random assignment
Number of subjects: 443
Study 32060547 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco prevention interventions (three types)
Number of subjects: 0
Study 32060547 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes and smokeless tobacco
Number of subjects: 0
Study 32060547 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarettes, cigarillos/little cigars, and hookah
Number of subjects: 0
Study 34512526 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic physical fitness training for four weeks
Number of subjects: 0
Study 34512526 — intervention group
Group type: COMPARATOR
Intervention: Relaxation sessions for four weeks (Control)
Number of subjects: 0
Study 34512526 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IL-6 and fibrinogen levels
Number of subjects: 0
Study 34512526 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP levels at 3 months after stroke
Number of subjects: 0
Study 34512526 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha levels
Number of subjects: 0
Study 35440458 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Interpersonal Psychotherapy (IPT) for perinatal loss
Number of subjects: 274
Study 35440458 — intervention group
Group type: COMPARATOR
Intervention: Group coping with depression (Control)
Number of subjects: 274
Study 34653648 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepsychiatry group (at least 50% of treatments via telemedicine, with at least one face-to-face treatment within six months)
Number of subjects: 0
Study 34653648 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face (FTF) group (all treatments conducted FTF, with no telemedicine)
Number of subjects: 0
Study 36387337 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 mg) oral tablets once daily for 6 months
Number of subjects: 70
Study 36387337 — intervention group
Group type: COMPARATOR
Intervention: Control (no pitavastatin)
Number of subjects: 70
Study 36387337 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 mg) oral tablets once daily for 6 months (HER2 positive subgroup)
Number of subjects: 70
Study 36387337 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 mg) oral tablets once daily for 6 months (HER2 negative subgroup)
Number of subjects: 70
Study 33814391 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 98
Study 33814391 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy with antioxidant medication
Number of subjects: 98
Study 33814391 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 98
Study 33529280 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 0
Study 36113491 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 0
Study 36113491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34489297 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 0
Study 34489297 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Number of subjects: 0
Study 34489297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 0
Study 32345170 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational treatment for RCC/UCC
Number of subjects: 253
Study 32345170 — intervention group
Group type: COMPARATOR
Intervention: Cough Severity Diary (CSD)
Number of subjects: 253
Study 35723686 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methylprednisolone (40 mg loading bolus followed by 40 mg/day for 7 days, then tapering over 20 days)
Number of subjects: 586
Study 35723686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 586
Study 35723686 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methylprednisolone
Number of subjects: 586
Study 34423525 — intervention group
Group type: EXPERIMENTAL
Intervention: Camelina sativa oil (CSO) 20g/d
Number of subjects: 46
Study 34423525 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sunflower oil) 20g/d
Number of subjects: 46
Study 32100943 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanogold-coated toothbrush
Number of subjects: 84
Study 32100943 — intervention group
Group type: COMPARATOR
Intervention: Uncoated toothbrush
Number of subjects: 84
Study 34260808 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical containing a blend of Glycine max, Cimicifuga racemosa, Vitex agnus-castus, and Oenothera biennis extracts administered over a 12-week period
Number of subjects: 110
Study 34260808 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical containing a blend of Glycine max, Cimicifuga racemosa, Vitex agnus-castus, and Oenothera biennis extracts
Number of subjects: 110
Study 34260808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 32770246 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Vaping Product (NVP)
Number of subjects: 100
Study 32770246 — intervention group
Group type: COMPARATOR
Intervention: Combination Nicotine Replacement Therapy (NRT)
Number of subjects: 100
Study 35312968 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual atropine sulfate 1% ophthalmic solution (0.5 mg and 1.0 mg)
Number of subjects: 15
Study 35312968 — intervention group
Group type: COMPARATOR
Intervention: 1.0 mg intravenous (IV) atropine dose
Number of subjects: 15
Study 35312968 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual atropine sulfate 1% ophthalmic solution
Number of subjects: 15
Study 33098041 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide-busulfan (CyBu)
Number of subjects: 70
Study 33098041 — intervention group
Group type: COMPARATOR
Intervention: busulfan-cyclophosphamide (BuCy)
Number of subjects: 70
Study 32485761 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosyllables
Number of subjects: 18
Study 32485761 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisyllables
Number of subjects: 18
Study 32485761 — intervention group
Group type: EXPERIMENTAL
Intervention: Trisyllables
Number of subjects: 18
Study 35551840 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct bonding of mandibular fixed retainers
Number of subjects: 64
Study 35551840 — intervention group
Group type: COMPARATOR
Intervention: Indirect bonding of mandibular fixed retainers
Number of subjects: 64
Study 34140765 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib (80 mg single dose on days 1 and 9) co-administered with Itraconazole (200 mg once-daily from days 6 to 22)
Number of subjects: 18
Study 34140765 — intervention group
Group type: COMPARATOR
Intervention: Pyrotinib (80 mg single dose on days 1 and 9)
Number of subjects: 18
Study 32810739 — intervention group
Group type: EXPERIMENTAL
Intervention: MitoQ (20 mg, 1 hour pre-exercise, chronic supplementation for 21 days)
Number of subjects: 24
Study 32810739 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 hour pre-exercise, chronic supplementation for 21 days)
Number of subjects: 24
Study 33859520 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral resveratrol (480 mg per day for 4 days)
Number of subjects: 8
Study 33859520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 32289294 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose photodynamic therapy (PDT)
Number of subjects: 42
Study 32289294 — intervention group
Group type: COMPARATOR
Intervention: High-density subthreshold micropulse laser (HSML)
Number of subjects: 42
Study 35284956 — intervention group
Group type: EXPERIMENTAL
Intervention: HybridAPC
Number of subjects: 39
Study 35284956 — intervention group
Group type: COMPARATOR
Intervention: Sharp excision
Number of subjects: 39
Study 34181475 — intervention group
Group type: EXPERIMENTAL
Intervention: XAV-19 at 0.5 mg/kg at day 1 and day 5 (group 1)
Number of subjects: 18
Study 34181475 — intervention group
Group type: EXPERIMENTAL
Intervention: XAV-19 at 2 mg/kg at day 1 and day 5 (group 2)
Number of subjects: 18
Study 34181475 — intervention group
Group type: EXPERIMENTAL
Intervention: XAV-19 at 2 mg/kg at day 1 (group 3)
Number of subjects: 18
Study 34181475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 33153527 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy–Emotion Development (PCIT-ED)
Number of subjects: 118
Study 33153527 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 118
Study 34348668 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine plus dexmedetomidine (group LD)
Number of subjects: 248
Study 34348668 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 248
Study 34348668 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine group (group L)
Number of subjects: 248
Study 34348668 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group (group D)
Number of subjects: 248
Study 35512155 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing: 1 g of IV TXA 30 min before skin incision, and 1 g at postoperative 30 min and 3 h.
Number of subjects: 99
Study 35512155 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based dosing: 10 mg/kg IV TXA 30 min before skin incision, and 10 mg/kg at postoperative 30 min and 3 h.
Number of subjects: 99
Study 35512155 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (standard and weight-based dosing of IV TXA).
Number of subjects: 99
Study 35758436 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological Speech and Language Therapy (SLA) for 4 weeks, initiated about a month after stroke
Number of subjects: 82
Study 35758436 — intervention group
Group type: COMPARATOR
Intervention: Neurological Speech and Language Therapy (SLA) for 4 weeks, initiated more than 6 months after stroke (late therapy)
Number of subjects: 82
Study 33534439 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) denervation combined with bupivacaine
Number of subjects: 76
Study 33534439 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone (control group)
Number of subjects: 76
Study 32207359 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 304
Study 32207359 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (20 IU)
Number of subjects: 304
Study 32207359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 33497028 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP+oxygen
Number of subjects: 60
Study 33497028 — intervention group
Group type: COMPARATOR
Intervention: Oxygen
Number of subjects: 60
Study 35945705 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-session brief intervention (MBI)
Number of subjects: 362
Study 35945705 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session brief intervention (SBI)
Number of subjects: 362
Study 35945705 — intervention group
Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 362
Study 34039473 — intervention group
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation (IRE) for margin accentuation during pancreaticoduodenectomy (PD)
Number of subjects: 111
Study 34039473 — intervention group
Group type: COMPARATOR
Intervention: Non-IRE (control group)
Number of subjects: 111
Study 32159859 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Universal Retreatment system + ProTaper Gold (PTG) instrumentation system up to PTG F2
Number of subjects: 65
Study 32159859 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc Blue system up to the instrument RB25
Number of subjects: 65
Study 32159859 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc system up to the instrument R25
Number of subjects: 65
Study 32159859 — intervention group
Group type: EXPERIMENTAL
Intervention: Wave One Gold (WOG) system up to the instrument WOG25
Number of subjects: 65
Study 36456912 — intervention group
Group type: EXPERIMENTAL
Intervention: Different cover letter information and incentives
Number of subjects: 960
Study 36456912 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading the cover letter carefully
Number of subjects: 960
Study 34037294 — intervention group
Group type: EXPERIMENTAL
Intervention: Considering COVID‐19 vaccination
Number of subjects: 1557
Study 34037294 — intervention group
Group type: EXPERIMENTAL
Intervention: Undecided about COVID‐19 vaccination
Number of subjects: 1557
Study 34037294 — intervention group
Group type: EXPERIMENTAL
Intervention: Not wanting COVID‐19 vaccination
Number of subjects: 1557
Study 34037294 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive factors for willingness to vaccination
Number of subjects: 1557
Study 34037294 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for a given vaccine
Number of subjects: 1557
Study 33736600 — intervention group
Group type: EXPERIMENTAL
Intervention: Persian version of the Respectful Maternity Care (RMC) questionnaire
Number of subjects: 150
Study 32089848 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention in social insurance medicine
Number of subjects: 100
Study 32089848 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study 32139090 — intervention group
Group type: EXPERIMENTAL
Intervention: BSC (halamine antimicrobial curtains)
Number of subjects: 0
Study 32139090 — intervention group
Group type: EXPERIMENTAL
Intervention: BSC-pre (halamine antimicrobial curtains sprayed twice weekly with sodium hypochlorite)
Number of subjects: 0
Study 32139090 — intervention group
Group type: COMPARATOR
Intervention: SC (standard curtain)
Number of subjects: 0
Study 34607172 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 44
Study 34668112 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialty Mental Health Probation (SMHP) officers
Number of subjects: 100
Study 34668112 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialty Mental Health Probation (SMHP)
Number of subjects: 100
Study 34668112 — intervention group
Group type: COMPARATOR
Intervention: Standard probation
Number of subjects: 100
Study 33468148 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot massage treatment (10-min daily for four weeks using sweet almond oil)
Number of subjects: 0
Study 33468148 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot massage treatment
Number of subjects: 0
Study 33468148 — intervention group
Group type: COMPARATOR
Intervention: Control group (no foot massage treatment)
Number of subjects: 0
Study 33468148 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35666314 — intervention group
Group type: EXPERIMENTAL
Intervention: OPERA® dietary supplement (α‐Lipoic acid, Boswellia serrata, Methylsulfonylmethane, and Bromelain) taken once a day for six months (T0 to T3)
Number of subjects: 53
Study 35666314 — intervention group
Group type: EXPERIMENTAL
Intervention: OPERA® dietary supplement
Number of subjects: 53
Study 34738701 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 172
Study 34738701 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 172
Study 33684596 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D supplementation
Number of subjects: 1788
Study 33684596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1788
Study 36266167 — intervention group
Group type: EXPERIMENTAL
Intervention: Submental flap reconstruction
Number of subjects: 0
Study 36266167 — intervention group
Group type: COMPARATOR
Intervention: Obturator rehabilitation
Number of subjects: 0
Study 32329437 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Approach to Sleep Health Education (TASHE)
Number of subjects: 194
Study 32329437 — intervention group
Group type: COMPARATOR
Intervention: Standard sleep information via the National Sleep Foundation website (Control)
Number of subjects: 194
Study 37323710 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 81
Study 37323710 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal training
Number of subjects: 81
Study 37323710 — intervention group
Group type: COMPARATOR
Intervention: Control (standard in-hospital treatment)
Number of subjects: 81
Study 35033635 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Number of subjects: 616
Study 35033635 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg
Number of subjects: 616
Study 35033635 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 616
Study 35033635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 616
Study 33445146 — intervention group
Group type: COMPARATOR
Intervention: CT (Concurrent Training)
Number of subjects: 45
Study 33445146 — intervention group
Group type: COMPARATOR
Intervention: CT + EL (Concurrent Training + Eurycoma longifolia)
Number of subjects: 45
Study 32063157 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised normal saline administered hourly
Number of subjects: 199
Study 32063157 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 199
Study 34323341 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified WHO cholera solution
Number of subjects: 27
Study 34323341 — intervention group
Group type: COMPARATOR
Intervention: Glucodrate® (Vitaflo)
Number of subjects: 27
Study 34121047 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate restriction at breakfast
Number of subjects: 43
Study 34121047 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate restriction at dinner
Number of subjects: 43
Study 35723003 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Light (1300 lux)
Number of subjects: 8
Study 35723003 — intervention group
Group type: COMPARATOR
Intervention: Dim Light (6 lux)
Number of subjects: 8
Study 33261635 — intervention group
Group type: EXPERIMENTAL
Intervention: HEAVY (progressive heavy shoulder strengthening programme)
Number of subjects: 100
Study 33261635 — intervention group
Group type: COMPARATOR
Intervention: LIGHT (low-load training and general advice)
Number of subjects: 100
Study 33261635 — intervention group
Group type: EXPERIMENTAL
Intervention: HEAVY
Number of subjects: 100
Study 33261635 — intervention group
Group type: COMPARATOR
Intervention: LIGHT
Number of subjects: 100
Study 33559186 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamidol
Number of subjects: 0
Study 33559186 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 0
Study 32423454 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific strengthening exercise
Number of subjects: 42
Study 32423454 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound
Number of subjects: 42
Study 36163766 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamibarotene/venetoclax/azacitidine
Number of subjects: 0
Study 36163766 — intervention group
Group type: COMPARATOR
Intervention: Venetoclax/azacitidine
Number of subjects: 0
Study 34024677 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative loading device for weightbearing CT imaging
Number of subjects: 10
Study 32418164 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized cognitive counseling (PCC)
Number of subjects: 153
Study 32418164 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 153